Edward Jones analyst Logan Purk upgrades Activision Blizzard (NASDAQ:ATVI) from Hold to Buy.
JP Morgan Downgrades Oyster Point Pharma to Neutral, Lowers Price Target to $23
JP Morgan analyst Anupam Rama downgrades Oyster Point Pharma (NASDAQ:OYST) from Overweight to Neutral and lowers the price target from $30 to $23.